Opinion

Video

Benefits of Incorporating Fusion-Guided Biopsy into Practice

Author(s):

David I. Lee, MD, FACS,Firas F. Abdollah, MD

Firas F. Abdollah, MD, provides insights on how MRI- or fusion-guided technologies are used with transrectal and transperineal biopsy procedures and how they improve traditional biopsy procedures.

Related Videos
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Woman typing on laptop | Image Credit: © Gorodenkoff - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Raevti Bole, MD, answers a question during a video interview
Related Content
Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer
December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke
“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Phase 2 trial launches of autologous prostate cancer vaccine
November 27th 2024

Phase 2 trial launches of autologous prostate cancer vaccine

Hannah Clarke
The phase 2 CELLVX-230 trial is exploring the potential of FK-PC101 to delay or prevent prostate cancer recurrence following prostatectomy.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC
November 25th 2024

Capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC

Hannah Clarke
Data from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.
Targeted microwave ablation shows precision, safety in localized prostate cancer
November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke
In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.
© 2024 MJH Life Sciences

All rights reserved.